TSTickerStarGet alerts

SION 10-Q filed 2026-11-10 | Key takeaways

SION filed its 10-Q; the most relevant disclosure change is added Restructuring plan: In September 2026, the board approved a restructuring plan including a 46% workforce reduction following the failure of the PreciSION CF Phase 2a trial for SION-719 as an add-on to Trikafta, with estimated aggregate restructuring charges of $6.4 million and $4.

Share this story

Key takeaways

  • Restructuring: Company announced a workforce reduction of approximately 46% in September 2026 following Phase 2a PreciSION CF trial failure for SION-719 as add-on to Trikafta

  • Restructuring charges: Approximately $6.2 million recognized in Q3 2026, consisting of $5.8 million in cash-related charges and $0.4 million in stock-based compensation; estimated total charges of $6.4 million

  • Stock option repricing: Board approved repricing of options to purchase 1,495,491 shares from exercise prices exceeding $18.00 to $7.18 per share effective September 17, 2026, with incremental compensation cost of approximately $3.4 million

  • Cash position: Cash, cash equivalents and marketable securities of $249.8 million as of September 30, 2026, expected to fund operations into second half of 2029

  • R&D pipeline shift: Company selected SION-451 + SION-2222 dual combination for advancement following Phase 1 trial; AscenSION CF Phase 2 proof-of-concept trial expected to initiate in Q1 2027

  • Nine-month net loss widened to $89.1 million from $54.8 million year-over-year, primarily due to increased development activities and personnel costs including stock-based compensation

  • Accrued expenses increased to $13.9 million from $9.7 million at year-end 2025, including approximately $4.1 million in restructuring-related liabilities

Key metrics

Net loss - Q3Three months ended September 30, 2026
$32.4 millionUp $12.1 million from $20.3 million in Q3 2025
Net loss - YTDNine months ended September 30, 2026
$89.1 millionUp $34.3 million from $54.8 million in prior year nine months
Net loss per share - Q3Three months ended September 30, 2026
$0.72Down from $0.46 in Q3 2025
Net loss per share - YTDNine months ended September 30, 2026
$1.98Down from $1.43 in prior year nine months
Research and development - Q3Three months ended September 30, 2026
$22.0 millionUp $6.0 million from $16.0 million in Q3 2025
General and administrative - Q3Three months ended September 30, 2026
$12.8 millionUp $5.0 million from $7.8 million in Q3 2025
Net cash used in operating activities - YTDNine months ended September 30, 2026
$62.8 millionUp from $49.7 million in prior year nine months
Cash and cash equivalentsSeptember 30, 2026
$83.9 million

Disclosure changes

  • Restructuring plan

    In September 2026, the board approved a restructuring plan including a 46% workforce reduction following the failure of the PreciSION CF Phase 2a trial for SION-719 as an add-on to Trikafta, with estimated aggregate restructuring charges of $6.4 million and $4.1 million in unpaid liabilities as of September 30, 2026

    Significant operational change that will reduce operating expenses and extend cash runway while refocusing on the SION-451 + SION-2222 dual combination program
  • Restructuring charges

    $6.2 million in restructuring and related charges recognized during three and nine months ended September 30, 2026, consisting of $5.8 million cash-related charges and $0.4 million non-cash stock-based compensation

    Material charge impacting Q3 results and providing transparency on cost reduction implementation
  • Stock option repricing

    On September 9, 2026, board approved repricing of options to purchase 1,495,491 shares held by 36 employees from exercise prices exceeding $18.00 per share to $7.18 per share, effective September 17, 2026, with incremental stock-based compensation cost of approximately $3.4 million

    Retention mechanism for employees following restructuring with associated compensation expense
  • Restricted stock units granted

    Company granted 703,050 RSUs to retained employees in connection with restructuring and retention program, consisting of time-based RSUs vesting after nine months and performance-based RSUs vesting upon achievement of a development milestone; 699,544 RSUs outstanding as of September 30, 2026

    Retention incentive for key employees amid restructuring with unrecognized stock-based compensation of $4.8 million
  • Clinical development pipeline update

    Company announced in August 2026 topline results from Phase 1 trial for SION-451 in dual combinations with SION-2222 and SION-109; selected SION-451 + SION-2222 for advancement; PreciSION CF Phase 2a trial for SION-719 failed to meet key activity endpoint with -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7); post hoc analysis identified potential confounding factors; AscenSION CF Phase 2 proof-of-concept trial expected to initiate Q1 2027

    Critical pipeline update following Phase 2 failure and selection of lead combination for future development
  • Accrued expenses

    Accrued expenses increased to $13.9 million as of September 30, 2026 from $9.7 million as of December 31, 2025, including approximately $3.6 million in accrued compensation and $0.5 million in accrued research and development related to restructuring

    Reflects restructuring-related liabilities and increased R&D activities

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow SION in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert